Dynavax Technologies (NASDAQ:DVAX) Upgraded by Cantor Fitzgerald to Overweight

Share on StockTwits

Cantor Fitzgerald upgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a neutral rating to an overweight rating in a research note issued to investors on Wednesday morning, BenzingaRatingsTable reports. The brokerage currently has $20.00 target price on the biopharmaceutical company’s stock.

A number of other research analysts also recently weighed in on DVAX. Zacks Investment Research raised shares of Gerdau from a sell rating to a hold rating in a research report on Monday, May 13th. William Blair reaffirmed a buy rating on shares of Dynavax Technologies in a report on Friday, June 21st. BidaskClub raised shares of Xilinx from a hold rating to a buy rating in a report on Saturday, June 29th. Cowen reaffirmed a buy rating on shares of Odonate Therapeutics in a report on Monday, June 3rd. Finally, Royal Bank of Canada reaffirmed a buy rating on shares of PrairieSky Royalty in a report on Friday, May 24th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Dynavax Technologies currently has a consensus rating of Buy and a consensus target price of $16.81.

Dynavax Technologies stock opened at $4.03 on Wednesday. Dynavax Technologies has a twelve month low of $3.57 and a twelve month high of $16.15. The company’s 50 day moving average is $4.25. The company has a quick ratio of 4.61, a current ratio of 5.27 and a debt-to-equity ratio of 4.88.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.05. Dynavax Technologies had a negative net margin of 1,156.11% and a negative return on equity of 190.84%. The firm had revenue of $5.77 million during the quarter, compared to the consensus estimate of $5.95 million. During the same period in the prior year, the firm earned ($0.63) EPS. The company’s revenue was up 3294.1% compared to the same quarter last year. On average, equities analysts expect that Dynavax Technologies will post -2.13 EPS for the current fiscal year.

In related news, SVP Robert Coffman sold 32,218 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $4.58, for a total value of $147,558.44. Following the completion of the transaction, the senior vice president now directly owns 132,470 shares of the company’s stock, valued at approximately $606,712.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.90% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. boosted its holdings in Dynavax Technologies by 515.3% in the 4th quarter. Advisor Group Inc. now owns 4,473 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 3,746 shares during the period. Quantamental Technologies LLC bought a new position in Dynavax Technologies in the 1st quarter worth approximately $62,000. BNP Paribas Arbitrage SA boosted its holdings in Dynavax Technologies by 56,326.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 12,978 shares of the biopharmaceutical company’s stock worth $95,000 after buying an additional 12,955 shares during the period. Pearl River Capital LLC bought a new position in Dynavax Technologies in the 1st quarter worth approximately $106,000. Finally, Legal & General Group Plc boosted its holdings in Dynavax Technologies by 18.7% in the 4th quarter. Legal & General Group Plc now owns 11,814 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,860 shares during the period. 81.94% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

See Also: Trading Stocks – What are percentage gainers?

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.